Drug updated on 4/10/2024
| Dosage Form | Tablet (oral; 10 mg, 20 mg, 40 mg) |
| Drug Class | Antidepressants |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of major depressive disorder (MDD) in adults.
Summary
- Vilazodone hydrochloride (Viibryd) is indicated for the treatment of major depressive disorder (MDD) in adults, but it may not be superior to other antidepressants such as amitriptyline, citalopram, and vortioxetine.
- Three studies reviewed compared vilazodone with 20 other antidepressants in terms of efficacy and safety.
- The first study suggests that desvenlafaxine, paroxetine, venlafaxine, and vortioxetine are more preferable due to their reasonable efficacy, acceptability, and tolerability profiles.
- The second study's findings on safety concerns and toxicity profile indicate that vilazodone poses serious risks, especially its potential to cause serotonin syndrome and seizures even at minimal doses in children, which highlights a concern for its use particularly among populations at risk for overdose or households with young children.
- The third study evaluated vilazodone’s pharmacokinetics and pharmacodynamics along with clinical utility for treating MDD and GAD. It suggested that while Viibryd is superior to placebo, it does not offer significant advantages over SSRIs or other currently used antidepressants, thus suggesting it as a second- or third-line treatment option only.
- Although effective against placebo, Viibryd does not seem to remarkably surpass several other antidepressant drugs available today, making further research necessary, especially larger studies, to fully understand this drug's place within MDD and GAD treatments amongst a plethora of available antidepressant options.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Viibryd (vilazodone hydrochloride) Prescribing Information. | 2023 | AbbVie Inc., North Chicago, IL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: A systematic review and network meta-analysis. | 2023 | Molecular Psychiatry |
| Vilazodone poisoning: A systematic review. | 2019 | Clinical Toxicology |
| Evaluation of vilazodone for the treatment of depressive and anxiety disorders. | 2019 | Expert Opinion on Pharmacotherapy |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Nonpharmacologic and Pharmacologic Treatments of Adults in the Acute Phase of Major Depressive Disorder: A Living Clinical Guideline From the American College of Physicians. | 2023 | Annals of Internal Medicine |
| Clinical Guidelines of the Egyptian Psychiatric Association for the Management of Treatment-Resistant Unipolar Depression in Egypt. | 2022 | Frontiers in Psychiatry |
| Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice. | 2022 | Neuropsychiatric Disease and Treatment |
| VA/DoD Clinical practice guideline for the management of major depressive disorder. | 2022 | The Management of Major Depressive Disorder Work Group |
| An updated classification of antidepressants: A proposal to simplify treatment | 2020 | Personalized Medicine in Psychiatry |